<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="227721">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00117143</url>
  </required_header>
  <id_info>
    <org_study_id>20010218</org_study_id>
    <nct_id>NCT00117143</nct_id>
  </id_info>
  <brief_title>Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)</brief_title>
  <official_title>An Open-Label, Unit Dose-Finding Study Evaluating the Safety and Efficacy of Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, and utility of AMG 531 unit
      dosing (Âµg) in thrombocytopenic subjects with ITP.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by the incidence and severity of all adverse events and the evaluation of antibody status.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving targeted platelet level (doubling of baseline platelet count and within 50 x 10^9/L to 450 x 10^9/L)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving specified increases and peak counts</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak count and time to peak</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration within targeted range</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <condition>Thrombocytopenic Purpura</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 531</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Greater than or equal to 3 months history if ITP, regardless of
        splenectomy status, and completion of at least 1 prior treatment for ITP - 2 of 3
        pretreatment platelet counts that were less than 30 x 10^9/L (if not currently on ITP
        therapy) or less than 50 x 10^9/L (if currently receiving corticosteroids for ITP therapy)
        - Ability to give informed consent Exclusion Criteria: - Known history of arterial
        thrombosis, active malignancy, or bone marrow stem cell disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <link>
    <url>http://www.nplate.com/</url>
    <description>FDA-approved Drug Labeling</description>
  </link>
  <results_reference>
    <citation>Newland A, Caulier MT, Kappers-Klunne M, Schipperus MR, Lefrere F, Zwaginga JJ, Christal J, Chen CF, Nichol JL. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol. 2006 Nov;135(4):547-53.</citation>
    <PMID>17061981</PMID>
  </results_reference>
  <verification_date>May 2009</verification_date>
  <lastchanged_date>May 21, 2009</lastchanged_date>
  <firstreceived_date>June 30, 2005</firstreceived_date>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>Immune Thrombocytopenic Purpura</keyword>
  <keyword>Idiopathic Thrombocytopenic Purpura</keyword>
  <keyword>ITP</keyword>
  <keyword>Thrombocytopenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
